# A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

> **NCT07554196** · PHASE1 · COMPLETED · sponsor: **Huahui Health** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HH-101 (0.3 mg/kg)
- **DRUG:** HH-101 (1 mg/kg )
- **DRUG:** HH-101 (3 mg/kg )
- **DRUG:** HH-101 (10 mg/kg)

## Key facts

- **NCT ID:** NCT07554196
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2023-08-09
- **Final completion:** 2024-03-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554196, "A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07554196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*